Research Article
Screening for Mild Cognitive Impairment in Parkinson’s Disease: Comparison of the Italian Versions of Three Neuropsychological Tests
Table 2
Characteristics of patients, according to the diagnosis and subtype of PD-MCI (MDS Task Force level II criteria).
| | No PD-MCI () | PD-MCI () | | Single-domain PD-MCI () | Multiple-domain PD-MCI () | |
| Age | 67.5 ± 11.2 | 68.9 ± 7.2 | n.s. | 65.5 ± 7.7 | 70.8 ± 6.2 | n.s. | Sex (M/F) | 12/9 | 15/7 | n.s. | 7/1 | 8/6 | n.s. | School (y) | 8.7 ± 3.1 | 8.3 ± 2.8 | n.s. | 9.3 ± 2.6 | 7.6 ± 2.8 | n.s. | Duration (y) | 7.8 ± 5.3 | 12.8 ± 8.1 | 0.03 | 13.1 ± 8.6 | 11.4 ± 8.1 | n.s. | H-Y (1–5) | 1.9 ± 0.7 | 2.5 ± 0.6 | 0.014 | 2.3 ± 0.8 | 2.6 ± 0.5 | n.s. | UPDRS-III (0–108) | 23.3 ± 8.9 | 30.2 ± 8.4 | 0.02 | 27.5 ± 10.2 | 31.5 ± 9.0 | n.s. | Treatment | | | | | | | LD (yes/no) | 17/4 | 20/2 | n.s. | 7/1 | 13/1 | n.s. | DA (yes/no) | 12/9 | 7/15 | n.s. | 2/6 | 5/9 | n.s. | MAO-I (yes/no) | 4/17 | 1/21 | n.s. | 0/8 | 1/13 | n.s. | Total LED (mg) | 821 ± 413 | 889 ± 394 | n.s. | 893 ± 439 | 888 ± 384 | n.s. | Depression (yes/no) | 8/13 | 9/13 | n.s. | 3/5 | 6/8 | n.s. |
|
|
School: education (years); duration: disease duration (years); H-Y: Modified Hoehn and Yahr Staging Scale (range 1–5); UPDRS-III: Unified Parkinson’s Disease Rating Scale part III (range 0–108); LD: levodopa; DA: dopamine agonist; MAO-I: monoamine oxidase inhibitors; LED: levodopa equivalent dose (daily).
|